文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

在美国和其他常规免疫仅使用灭活脊髓灰质炎病毒疫苗(IPV)的国家中,不同脊髓灰质炎病毒疫苗用于疫情应对的权衡

Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
PubMed 文献 · Vaccine · 2024-01-12

为应对消灭脊髓灰质炎进展延迟带来的输入与暴发风险,本文系统综述了IPV疫情应对的建模研究,并基于2022年纽约2型脊髓灰质炎病毒暴发模型,比较不同OPV与IPV用于疫情应对的后果。研究发现IPV仅在整体免疫覆盖率极高、传播潜力较低且存在季节性传播动态、干预能触及部分未接种者时可能终止暴发;在仅用IPV国家使用OPV应对疫情存在 substantial 风险与挑战,但可能在某些人群的某些暴发中作为可考虑选项。

要点

  • 在仅用IPV国家,IPV用于疫情应对可能仅在传播潜力较低、整体免疫覆盖率极高且存在季节性传播动态时终止暴发。
  • 使用OPV应对仅用IPV国家的疫情存在 substantial 风险与挑战,需审慎考虑。
  • OPV可能作为某些暴发的可考虑选项,取决于可用疫苗特性和可达到的覆盖率。

核心结论

  • 在仅用IPV国家,IPV用于疫情应对可能仅在传播潜力较低、整体免疫覆盖率极高且存在季节性传播动态时终止暴发,且IPV干预需触及部分未接种者。
  • 在仅用IPV国家使用OPV应对疫情存在 substantial 风险与挑战,需审慎考虑,但可能在某些人群的某些暴发中作为可考虑选项,取决于可用疫苗特性和可达到的覆盖率。

研究设计与样本

  • 系统综述文献以识别探讨在仅用IPV国家使用IPV进行疫情应对的建模研究。
  • 应用2022年纽约2型脊髓灰质炎病毒暴发模型,刻画使用不同OPV制剂替代IPV进行疫情应对的影响。
  • 探索将同一暴发假设为1型脊髓灰质炎病毒而非2型的场景。

主要发现

  • 使用IPV进行疫情应对可能仅在传播潜力相对较低的脊髓灰质炎病毒、整体免疫覆盖率极高的国家、存在季节性传播动态且IPV免疫干预触及部分未接种者时终止暴发。
  • 在仅用IPV国家使用OPV进行疫情应对存在 substantial 风险与挑战,需审慎考虑。
  • OPV可能作为某些暴发的可考虑选项,取决于可用疫苗特性和可达到的覆盖率。

临床怎么用

  • 作者认为,在仅用IPV国家使用OPV应对疫情存在 substantial 风险与挑战,需审慎考虑,但可能在某些人群的某些暴发中作为可考虑选项,取决于可用疫苗特性和可达到的覆盖率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Delays in achieving polio eradication have led to ongoing risks of poliovirus importations that may cause outbreaks in polio-free countries. Because of the low, but non-zero risk of paralysis with oral poliovirus vaccines (OPVs), countries that achieve and maintain high national routine immunization coverage have increasingly shifted to exclusive use of inactivated poliovirus vaccine (IPV) for all preventive immunizations. However, immunization coverage within countries varies, with under-vaccinated subpopulations potentially able to sustain transmission of imported polioviruses and experience local outbreaks. Due to its cost, ease-of-use, and ability to induce mucosal immunity, using OPV as an outbreak control measure offers a more cost-effective option in countries in which OPV remains in use. However, recent polio outbreaks in IPV-only countries raise questions about whether and when IPV use for outbreak response may fail to stop poliovirus transmission and what consequences may follow from using OPV for outbreak response in these countries. We systematically reviewed the literature to identify modeling studies that explored the use of IPV for outbreak response in IPV-only countries. In addition, applying a model of the 2022 type 2 poliovirus outbreak in New York, we characterized the implications of using different OPV formulations for outbreak response instead of IPV. We also explored the hypothetical scenario of the same outbreak except for type 1 poliovirus instead of type 2. We find that using IPV for outbreak response will likely only stop outbreaks for polioviruses of relatively low transmission potential in countries with very high overall immunization coverage, seasonal transmission dynamics, and only if IPV immunization interventions reach some unvaccinated individuals. Using OPV for outbreak response in IPV-only countries poses substantial risks and challenges that require careful consideration, but may represent an option to consider for some outbreaks in some populations depending on the properties of the available vaccines and coverage attainable.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thompson KM, Kalkowska DA, Kidd SE, et al. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. Vaccine. 2024. PMID: 38218668. doi:10.1016/j.vaccine.2023.12.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。